

Amendments to the Specification:

Please amend the specification as follows:

On page 1, please delete paragraph [0001] and replace it with the following paragraph:

[0001] This application claims priority of and is a U.S. national phase application of PCT/US2004/013852, filed May 3, 2004, which claims priority of U.S. Provisional Application No. 60/467,177, filed May 1, 2003.

On page 18, please delete paragraph [0081] and replace it with the following paragraph:

[0081] In another embodiment, the present antibodies, or fragments thereof, can have a heavy chain variable region of SEQ ID NO:2 and/or a light chain variable region selected from SEQ ID NO:6 or SEQ ID NO:10. IMC-A12 is a particularly preferred antibody of the present invention. This antibody has human V_H and V_L framework regions (FWs) as well as CDRs. The V_H variable domain of IMC-A12 (SEQ ID NO:2) has three CDRs corresponding to SEQ ID NOS:14, 16, and 18 and the V_L domain (SEQ ID NO:10) has three CDRs corresponding to SEQ ID NOS:26, 28, and 30. IMC-2F8 is another preferred antibody of the present invention. This antibody also has human V_H and V_L framework regions (FWs) and CDRs. The V_H variable domain of IMC-2F8 is identical to the V_H variable domain of IMC-A12. The V_L domain of IMC-2F8 (SEQ ID NO:6) has three CDRs corresponding to SEQ ID NOS:20, 22, and 24.